After certain kinds of injuries or wounds — think heart attacks, burns and tendon tears, among others — scar tissue can form ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...

Fibrosis in multiple organs is a prominent pathological finding and distinguishing hallmark of systemic sclerosis (SSc). Findings during the past 5 years have contributed to a more complete ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Intestinal fibrosis is a common and potentially serious complication of IBD that results from the reaction of intestinal tissue to the damage inflicted by chronic inflammation. The traditional view ...

The Driven Brands Collision Group, the parent company of leading collision repair brands including Abra,CARSTAR, and Fix Auto USA announced that it has surpassed $6 million raised for cystic fibrosis ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

People in Lexington got a chance to experience an elaborate holiday display Sunday while supporting a good cause.

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...